English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Potjagenko M., Sokoluk N., Shepitko K., Gayevskiy S., Potjagenko V.

    BY CHRONIC OBSTRUCTIVE DISEASES OF LUNGS IN COMBINATION WITH HYPERTENSIS


    About the author: Potjagenko M., Sokoluk N., Shepitko K., Gayevskiy S., Potjagenko V.
    Heading CLINICAL MEDICINE
    Type of article Научная статья
    Annotation Studied the effect of Cardosal was investigated in complex therapy of patients by the chronic obstructive diseases of lungs in combination with a hypertensis. For patients which got Cardosal, there was an effective decline SAP and DAP, diminishing of clinical displays of hypertensis. It is shown that Cardosal has high efficiency, low-toxic and in therapeutic doses well carried by patients, may be the drug of choice in therapy of chronic obstructive diseases of lungs in combination with a hypertensis.
    Tags кардосал, chronic obstructive diseases of lungs, hypertensis.
    Bibliography
    • Наказ МОЗ України №128. Про затвердження клінічних протоколів надання медичної допомоги за спеціальністю «Пульмонологія». Київ-2007р.
    • Лапач С.Н. Статистические методы в медико-биологических исследованиях с использованием Excel / С.Н. Лапач, А.В. Чубенко, П.Н. Бабич. - К.: Морион, 2001.- 408с.
    • Рекомендації Українського товариства кардіологів з профілактики та лікування артеріальної гіпертензії. - К., 1999.- 51с.
    • Свищенко Е.П. Артериальная гипертензия. Практическое руководство / Е.П. Свищенко, В.Н. Коваленко. - К.: Морион, 2001.- 528с.
    • Сидоренко Б.А. Блокатор АТ-1 ангиотензиновых рецепторов лозартан. Часть 1 / Б.А. Сидоренко Д.В. Преображенский, Т.М. Стеценко // Основы клинической фармакологии. Кардиология. - 2002. - №1. - С.90-97.
    • Anderson O.K. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist in comparison with losartan / O.K. Anderson, S. Neldam // Blood Press. - 1999. - Vol. 7. - P. 53-59.
    • Cardiovascular norbiditly and mortality in patients with diabetes in the losartan intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol / L.H. Lindholm, H. Ibsen, Dahlof [et al.] // Lancet. - 2002.-Vol.359. - P. 1004-1010.
    • Goldberg A.I. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonists, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin – converting enzyme inhibitors for the treatment of systemic hypertension / A.I. Goldberg, M.C. Dunlay, C.S. Sweet // Am.J.Cardiol. - 1995. - Vol. 75. - P. 793-795.
    • Kincaid-Smith P. Randomizet controlled crossover of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonists to angiotensin converting enzyme inhibitor in normotensive parients with chronic renal disease and proteinuria / P. Kincaid-Smith, K. Fairley, D. Packham // Nephr. Dial. Transplant. - 2002. - Vol. 17. - P. 597-601.
    Publication of the article «World of Medicine and Biology» №3(26), 2010 year, 35-37 pages, index UDK 616.24-0022:616